⌘K

11:39:12·1168d

13D/GFilingvia Quantisnow

SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)

ByQuantisnow·Wall Street's wire, on your screen.

ORTX· Orchard Therapeutics plc

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
ORI Capital Raises $260 Million for Second Life Sciences Fund

SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment) | Quantisnow